TheranosticTrials.org

Clinical Trial · NCT07753499

Trophoblast Cell-Surface Antigen 2 (Trop-2) Targeted PET/CT in Recurrent and Metastatic Thyroid Cancer

Overview

In this study, we comprehensively evaluated the clinical utility of Trop2 PET/CT (68Ga-MY6349 PET/CT) imaging for detecting recurrent and metastatic thyroid cancer, and the results were compared with those of 68Ga-FAPI PET/CT. The primary objective of this study was to evaluate the patient-based sensitivity of 68Ga-MY6349 PET/CT in detecting recurrent and metastatic thyroid cancer. The secondary objectives included its overall specificity, lesion-based diagnostic performance, comparative tumor uptake relative to 68Ga-FAPI PET/CT, and the impact on clinical management.

Sponsor

The First Affiliated Hospital of Xiamen University

Phase

N/A

Contacts

Haojun Chen, MD, PhD

leochen0821@foxmail.com

18659285282

Hao Fu, MD, PhD

fuhaonuclear@163.com

15959230059

ClinicalTrials.gov

NCT07753499

Drug / Compound

FAPI

Isotope(s):
Target(s):
  • FAP
Ligand Class: Small Molecules
Chelator: DOTA

MY6349

Isotope(s):
Target(s):
  • Trop-2
Ligand Class: Peptides

Eligibility

Inclusion

  • No other anticancer therapy within four weeks prior to PET imaging.
  • Patients with a history of previously treated thyroid cancer, including DTC and HGFCTC following thyroidectomy with or without 131I therapy, MTC after thyroidectomy, or ATC; either (1) evidence of structural or suspicious lesions on standard of care imaging or (2) biochemical evidence of disease in the absence of structural findings, defined as elevated thyrotropin suppressed thyroglobulin (Tgon ≥1 ng/mL after 131I ablation or ≥5 ng/mL without ablation) with negative anti thyroglobulin antibodies (\<20 IU/mL) for DTC and HGFCTC or elevated calcitonin (\>10 pg/mL) for MTC;
  • Patients who had scheduled both 68Ga-MY6349 and 68Ga-FAPI PET/CT scans;

Exclusion

Exclusion criteria not yet provided.